
The sudden death of former SurveyMonkey CEO Dave Goldberg nine years ago shook Iconiq Capital founder Divesh Makan. He had first met Goldberg and his wife, former Facebook chief operating officer Sheryl Sandberg, in 2002, when all three of them were still “nobodies,” as Makan puts it.
“It was the first real death that I had in my life,” Makan told Fortune in an interview. “It was the first death I felt.”
Goldberg had been an important client at Iconiq Capital, the investment firm that Makan cofounded after leaving Morgan Stanley in 2011 with a roster of wealthy tech and celebrity clients. But most significantly, Goldberg had been a close friend and mentor to Makan. Right up to his passing, Makan says, he and Goldberg spoke via phone, text, or email almost daily—and the intimate dinners Goldberg hosted at his house shaped how Makan thought about the word “community.”
It was Goldberg who encouraged Makan to launch Iconiq Growth, now the investment firm’s venture capital arm, in 2013, and who would write the fund one of its largest initial checks. He helped persuade Will Griffith, who had worked at the venture investing shop TCV for nine years, to join and launch it (and school him in poker in the meantime, Griffith says). Goldberg also helped the fund land some of its first deals, and he sat on the firm’s first advisory board.
“He was our biggest reference source. He was our biggest critic. He was our biggest advocate. And he was our biggest cheerleader—all in one,” Makan says of Goldberg.
Esta historia es de la edición DEEP DIVES: Special Digital Issue de Fortune US.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición DEEP DIVES: Special Digital Issue de Fortune US.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar

The Blackstone Edge
90 DAYS. DOZENS OF INTERVIEWS. BILLIONS ON THE LINE. HOW BLACKSTONE'S CEO-MAKER GETS THE JOB DONE.

When Elon Musk has a really tough job, he turns to Steve Davis. DOGE might do the same.
IT WAS THE FALL OF 2022 when employees at Elon Musk's Boring Company began to notice Steve Davis wasn't around.

ASK ANDY - SHOULD MY STARTUP RAISE MONEY FROM VCS? IF SO, WHICH ONES DO I CHOOSE?
A FRIEND—I’ll call him Allen—spent years bootstrapping his real estate enterprise software company. After a long struggle to get to $1 million in sales, his business recently surged to $10 million, and revenue is now growing 100% year on year.

ELLIOTT HILL - JUST DOING IT
Staffers and brand loyalists cheered when Nike's new CEO came out of retirement to lead the company he has had an “irrational love” for since he began there as an intern. Turning it around will take more than good vibes.

HOW TO PLAN YOUR NEXT $100,000 VACATION
ON AN EXCURSION to the ancient city of Petra, Jordan, clients helicoptered in after-hours so they could tour the ruins alone.

THE BATTLE OVER AG1
Influencers are fighting over it. Scientists scoff at it. But the $100-a-month powder once known as Athletic Greens is only getting more popular.

THE WORKPLACE - GEN ZERS WANT TO BE THEIR OWN BOSS.CAN THE CORPORATE WORLD WOO THEM BACK?
CHASE GALLAGHER WAS 12 years old when he started mowing his neighbors' lawns in Chester County, Pa., for $35 a pop in the summer of 2013. At first the Gen Zer had only two customers, but thanks to some aggressive leafleting, he had 10 clients by the following year.

How much can DOGE do?
Elon Musk and Donald Trump aim to cut as much as $2 trillion in federal spending. It'll be even harder than it sounds.

YOUNG PEOPLE ARE DRINKING LESS ALCOHOL. CAN CEO MICHEL DOUKERIS PERSUADE THEM TO KEEP DRINKING AB INBEV'S BEERS?
SOME TIME AGO, top CEOs at an invitation-only seminar at Harvard Business School were asked to imagine the four crises they would likely confront during their tenure at the top: a health emergency, a geopolitical conflict, an economic downturn, and a trade war.

America's drug middlemen are now a $557 billion industry. Can Trump and his allies 'knock out' PBMs?
IN LATE DECEMBER, President-elect Donald Trump put pharmacy benefit managers, or PBMs, on notice.